INTRECOM communication BCI study

The INTRECOM study evaluates ABILITY Neurotech’s fully implantable communication BCI at UMC Utrecht, with Medical Research Ethics Committee approval. Per the company’s study page:

• participants: ages 18 to 70 with severe paralysis and speech problems from traumatic brain injury, stroke, neurodegenerative or neuromuscular disease (including ALS); still able to communicate by other means such as eye blinking; cognitively unimpaired
• the study lasts about one year, with home-based training and a goal of independent home use
• clinical lead: Dr Mariska Vansteensel, Associate Professor at UMC Utrecht

Trade press reported on Oct 12-13, 2026 that the company had begun first-in-human testing; the company’s own study page confirms recruiting but does not state an implant date, so that milestone is reported-only here.

Primary sources

• ABILITY study page
• Medical Product Outsourcing (Oct 12, 2026)